Judges Scientific plc
(the "Company")
Issue of equity and Director/PDMR shareholding
Further to the announcement of 24 July 2015 disclosing an irrevocable instruction given by David Barnbrook, a Director of the Company, to sell 5,000 Ordinary Shares in the Company primarily to fund the exercise cost and tax liability associated with the exercise of 5,000 options over new Ordinary Shares in the Company prior to their expiration date of 19 October 2015. The Company announces that it has, today, issued 5,000 new ordinary shares of 5p each ("New Shares") under its existing blocklisting to satisfy the exercise of options by David Barnbrook, a director of Judges, under the Company's Unapproved Share Option Scheme. David Barnbrook has subsequently sold the New Shares.
Director |
Existing shareholding |
Number of options exercised |
Exercise price (£) |
Shares sold |
Sale price (£) |
Resultant shareholding |
Resultant shareholding (%) |
David Barnbrook |
21,953 |
5,000 |
1.015 |
5,000 |
14.00 |
21,953 |
0.36 |
In addition, David holds remaining options over 23,325 ordinary shares under the Company's Share Option Plans.
The Group's share capital and total voting rights now comprises of 6,097,049 ordinary shares of 1p each. The Group does not hold any shares in treasury. Consequently, 6,097,049 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Group under the FCA's Disclosure and Transparency Rules.
For further information please contact:
For further information please contact:
Judges Scientific Plc
David Cicurel, CEO
Brad Ormsby, Group FD
Tel: 020 3829 6970
Shore Capital (Nominated Adviser & Broker)
Pascal Keane
Edward Mansfield
Tel: 020 7408 4090
Cardew Group (Financial Public Relations)
Nadja Vetter
Tel: 020 7930 0777 or 07941 340 836